Cargando…

Pain in the neurodegenerating brain: insights into pharmacotherapy for Alzheimer disease and Parkinson disease

Detalles Bibliográficos
Autores principales:	Lawn, Timothy, Aman, Yahyah, Rukavina, Katarina, Sideris-Lampretsas, George, Howard, Matthew, Ballard, Clive, Ray Chaudhuri, Kallol, Malcangio, Marzia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2021
Materias:	Topical Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7977618/ https://www.ncbi.nlm.nih.gov/pubmed/33239526 http://dx.doi.org/10.1097/j.pain.0000000000002111

Ejemplares similares

Reduced thermal sensitivity and increased opioidergic tone in the TASTPM mouse model of Alzheimer's disease
por: Aman, Yahyah, et al.
Publicado: (2016)

CD206(+)/MHCII(−) macrophage accumulation at nerve injury site correlates with attenuation of allodynia in TASTPM mouse model of Alzheimer's disease
por: Silva, Rita, et al.
Publicado: (2022)

Potential of animal models for advancing the understanding and treatment of pain in Parkinson’s disease
por: Buhidma, Yazead, et al.
Publicado: (2020)

Parkinson's disease and Covid-19: Is there an impact of ethnicity and the need for palliative care
por: Rukavina, Katarina, et al.
Publicado: (2022)

Galectin-3 activates spinal microglia to induce inflammatory nociception in wild type but not in mice modelling Alzheimer’s disease
por: Sideris-Lampretsas, George, et al.
Publicado: (2023)

Dorsal root ganglia CX3CR1 expressing monocytes/macrophages contribute to arthritis pain
por: Oggero, Silvia, et al.
Publicado: (2022)

Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options
por: Cummings, Jeffrey L., et al.
Publicado: (2019)

Silencing miR-21-5p in sensory neurons reverses neuropathic allodynia via activation of TGF-β–related pathway in macrophages
por: Zeboudj, Lynda, et al.
Publicado: (2023)

Parkinson's Disease and Post–COVID‐19 Syndrome: The Parkinson's Long‐COVID Spectrum
por: Leta, Valentina, et al.
Publicado: (2021)

Impaired chronic pain‐like behaviour and altered opioidergic system in the TASTPM mouse model of Alzheimer's disease
por: Aman, Y., et al.
Publicado: (2018)

Coronavirus Disease 2019 and Related Parkinsonism: The Clinical Evidence Thus Far
por: Boura, Iro, et al.
Publicado: (2022)

Treatment paradigms in Parkinson's Disease and Covid-19
por: Boura, Iro, et al.
Publicado: (2022)

Effects of safinamide on pain in patients with fluctuating Parkinson's disease
por: Grigoriou, Sotirios, et al.
Publicado: (2021)

Basic mechanisms of urgency: roles and benefits of pharmacotherapy
por: Michel, Martin Christian, et al.
Publicado: (2009)

Novel Pharmacotherapies in Parkinson’s Disease
por: Tizabi, Yousef, et al.
Publicado: (2021)

Periaqueductal grey and spinal cord pathology contribute to pain in Parkinson’s disease
por: Buhidma, Yazead, et al.
Publicado: (2023)

Serotonergic dysregulation is linked to sleep problems in Parkinson's disease
por: Wilson, Heather, et al.
Publicado: (2018)

Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson’s disease
por: Oikonomou, Panteleimon, et al.
Publicado: (2021)

Shared Mechanisms of Neurodegeneration in Alzheimer's Disease and Parkinson's Disease
por: Xie, Anmu, et al.
Publicado: (2014)

A perceptive plus in Parkinson's disease
por: Himmelberg, Marc M., et al.
Publicado: (2018)

Ethnic Disparities in Treatment of Chronic Pain in Individuals with Parkinson's Disease Living in the United Kingdom
por: Rukavina, Katarina, et al.
Publicado: (2022)

Factors Affecting Adherence to Pharmacotherapy in Parkinson's Disease
por: Aggarwal, Shivaansh, et al.
Publicado: (2021)

Covid-19 and Parkinson's disease: Acute clinical implications, long-COVID and post-COVID-19 parkinsonism
por: Leta, Valentina, et al.
Publicado: (2022)

Drooling in Parkinson’s Disease: Prevalence and Progression from the Non-motor International Longitudinal Study
por: van Wamelen, Daniel J., et al.
Publicado: (2020)

Sleep disturbances and gastrointestinal dysfunction are associated with thalamic atrophy in Parkinson’s disease
por: Niccolini, Flavia, et al.
Publicado: (2019)

Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson’s disease
por: Lau, Yue Hui, et al.
Publicado: (2022)

Neurodegeneration and neuroprotection in Parkinson's disease /
Publicado: (1996)

Combination pharmacotherapy in Alzheimer's disease
por: Mintzer, Jacobo, et al.
Publicado: (2003)

The range and nature of non-motor symptoms in drug-naive Parkinson’s disease patients: a state-of-the-art systematic review
por: Zis, Panagiotis, et al.
Publicado: (2015)

Tobacco Cessation Interventions in Dental Networks: A Practice-based Evaluation of the Impact of Education on Provider Knowledge, Referrals, and Pharmacotherapy Use
por: Pronk, Nicolaas P, et al.
Publicado: (2006)

The Role of Microglia in Retinal Neurodegeneration: Alzheimer's Disease, Parkinson, and Glaucoma
por: Ramirez, Ana I., et al.
Publicado: (2017)

Genetics of Alzheimer’s disease
por: König, Theresa, et al.
Publicado: (2021)

Parkinson's Impulse‐Control Scale for the Severity Rating of Impulse‐Control Behaviors in Parkinson's Disease: A Semistructured Clinical Assessment Tool
por: Okai, David, et al.
Publicado: (2016)

Adherence to Pharmacotherapy in Patients With Parkinson's Disease Taking Three and More Daily Doses of Medication
por: Straka, Igor, et al.
Publicado: (2019)

Cyclooxygenase and Neuroinflammation in Parkinson’s Disease Neurodegeneration
por: Bartels, Anna L, et al.
Publicado: (2010)

Parkinson’s disease managing reversible neurodegeneration
por: Hinz, Marty, et al.
Publicado: (2016)

Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease
por: Gelders, Géraldine, et al.
Publicado: (2018)

Perceptions of symptoms and expectations of advanced therapy for Parkinson’s disease: preliminary report of a Patient-Reported Outcome tool for Advanced Parkinson’s disease (PRO-APD)
por: Reddy, Prashanth, et al.
Publicado: (2014)

Drug Interactions in Parkinson’s Disease: Safety of Pharmacotherapy for Arterial Hypertension
por: Bitner, Anna, et al.
Publicado: (2015)

Modified Iron Deposition in Nigrosomes by Pharmacotherapy for the Management of Parkinson’s Disease
por: Wang, Mengdi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o6vdlp4rkkuhal3mhs2i02jfo4